Sweden Prothrombin Complex Concentrate (PCC) Market Outlook

swedish prothrombin complex concentrate (pcc) is a clotting factor concentrate that has been manufactured in concentrated form for over the last 50 years. in sweden, pcc is mainly prescribed for prophylaxis and treatment of bleeding in patients with deficits of clotting factors like hemophilia a and b, von willebrand disease, and glanzman’s thrombasthenia. over the next few years, there is expected to be an increased demand for pcc in sweden due to a number of factors that involve a growing elderly population, an increasing prevalence of rare diseases, and a surge in lifestyle-related ly-associated thrombotic disorders. as per the estimates of the world health organization, the swedish population aged 65 and above will increase by more than 15%, from 1.4 million in 2012 to 1.7 million in 2020. with age comes an increase in the prevalence of diseases, and thrombotic disorders are most common among the elderly. this can lead to an increasing demand for treatment and prophylactic use of pcc in order to prevent fatal bleeding in patients with clotting factor deficiencies. the increasing prevalence of rare diseases resulting from genetic mutations is also expected to substantially increase the demand for pcc in sweden. hemophilia is caused by mutations in a gene, and according to the organisation for rare disease india, there are about 3000-5000 known cases in sweden living with the condition. von willebrand disease is also a rare bleeding disorder and is estimated to affect as many as 0.2–0.7% of the population in sweden. the rise in lifestyle-related co-morbidities like hypertension, obesity, diabetes and other ailments can lead to an increase in thrombotic disorders, as such conditions increase the risk of blood clotting, especially in elderly patients. this can result in a surge in demand for pcc in sweden. overall, the increased demand for pcc in sweden over the next few years can be attributed to a growing elderly population, an increase in the prevalence of rare diseases, and a surge in lifestyle-related co-morbidities. pcc is an important part of everyday medical practice in sweden and is expected to remain so in the foreseeable future.